Drug intelligence / Profile preview

tumor necrosis factor-α

Development stage
Phase 3
Lead developer
TNF Pharmaceuticals
Modality
Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
01

Overview

Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine produced primarily by activated macrophages and other immune cells. It plays a central role in inflammation and immune regulation. In the context of disease treatment, most clinical applications target inhibition of TNF-α rather than administration of the cytokine itself. However, in experimental settings such as cancer therapy (e.g., intratumoral injection for pancreatic cancer), recombinant or adenovector-delivered TNF-α has been investigated for its ability to induce tumor cell death and enhance immune responses[6][8]. The mechanism involves binding to specific receptors on target cells, leading to activation of signaling pathways that can result in apoptosis or necroptosis.

Other names
Tumor Necrosis Factor-alphaCachectinTNFalpha
02

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)

Beyond the preview

Go deeper on tumor necrosis factor-α.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tumor necrosis factor-α.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call